Physician profile
Mark Scheier
NPI 1073516076
$7,477.39
in general payments reported to CMS, 2019-2025
39 companies · $913 in 2025
The $913 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $1,193 · 2021: $2,704 · 2022: $430 · 2023: $357 · 2024: $922 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,598.97 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $792.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $673.86 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $415.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $358.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.50 | 2019-2023 | Jardiance, Tradjenta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $344.61 | 2025 | Caplyta |
| Novo Nordisk INC | $322.98 | 2020-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $301.75 | 2021-2025 | Teflaro |
| Indivior INC. | $192.38 | 2019-2020 | |
| Allergan, INC. | $177.87 | 2019-2020 | |
| Glaxosmithkline, LLC. | $169.59 | 2020-2024 | Arexvy |
| Sunovion Pharmaceuticals INC. | $167.19 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $157.92 | 2019-2025 | Verquvo |
| Gilead Sciences, INC. | $150.68 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Scheier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.